All In Biotech

Drug Trial Radar · NCT05979051

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)

A Multicenter, Single-arm/Randomized, Double-blind, Active-controlled, Parallel-group Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR-1703 for Patients With EGPA

Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

166

Planned (sponsor's estimate)

Start

Nov 16, 2023

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Aug 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.

Conditions

  • Eosinophilic Granulomatosis With Polyangiitis

Interventions

  • SHR-1703Drug

    SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.

  • Mepolizumab InjectionDrug

    Mepolizumab Injection and Matching Placebo will be administered by Subcutaneous injection in Phase 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in oral glucocorticoid dose (OCS)Time frame: Up to week 12
  2. The Proportion of subjects in EGPA remissionTime frame: week 36 and week 48

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.